RxDoctor Payments Data

Shubi Shahida, MD

Internal Medicine · Smithfield, NCNPI 1407803562

Payments from drug & device makers

$12,458in general payments, 2019–2025

Across 870 payments — averaging $14.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$2K
  • GSK$1K
  • AbbVie$885
  • Merck$858
  • Amgen$710
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$12,24398%
  • Education$2152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$12,458 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$254,073
Medicare patients
380
Services billed
4,626

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban260$204,702
OzempicSemaglutide169$203,858
Trelegy ElliptaFluticasone/Umeclidin/Vilanter260$197,196
JardianceEmpagliflozin220$181,609
MounjaroTirzepatide111$154,841
JanuviaSitagliptin Phosphate83$79,568
RybelsusSemaglutide63$78,525
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog64$72,194
LinzessLinaclotide91$64,672
Tresiba Flextouch U-200Insulin Degludec40$58,066
BiktarvyBictegrav/Emtricit/Tenofov Ala13$51,358
Dupixent PenDupilumab13$48,453
KerendiaFinerenone67$47,707
FarxigaDapagliflozin Propanediol55$46,896
GlyxambiEmpagliflozin/Linagliptin58$46,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Xultophy 100-3.6$1,832$297,290244 claims
Boehringer IngelheimJardiance, Glyxambi, Tradjenta, Combivent Respimat$289$278,483344 claims
GSKTrelegy Ellipta, Breo Ellipta$1,014$215,534299 claims
PfizerEliquis$299$204,702260 claims
Lilly USA, LLCMounjaro, Trulicity$447$194,663145 claims
MerckJanuvia, Janumet Xr, Lagevrio (Eua), Janumet, Belsomra$858$139,891174 claims
AbbVieLinzess, Vraylar, Qulipta, Synthroid, Namzaric$885$120,510286 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,789$65,15080 claims
GileadBiktarvy$17$51,35813 claims
BayerKerendia$329$47,70767 claims
NovartisEntresto$297$40,64649 claims
Astellas Pharma US IncMyrbetriq$221$25,37639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Smithfield

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →